ReviewNeuro-oncology practice2025
Opportunities and challenges in application of VASARI features in neuro-oncology.
Review in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of objective radiological data in glioma research remains an underexplored opportunity in neuro-oncology. Despite multiple efforts to incorporate radiomic features in glioma analysis, the lack of a unified imaging reporting system in gliomas prevents large-scale, multi-center scientific collaborations from integrating comparable imaging variables to their work. VASARI lexicon, a set of 30 semantic radiomic features using controlled vocabulary and visual guides, was created to become a shared language for neuroscientists evaluating gliomas. It has been proven, that VASARI features are not only reliably correlated with various genetic aberrations but are also increasingly included in numerous statistical and machine learning models for predicting overall survival, tumor recurrence, glioma grade, and tumor molecular characteristics. In this review, we present an overview of VASARI application in prediction modeling, including the best-performing models and relevance of VASARI features depending on the predicted outcomes. We delve into the opportunities related to the inclusion of VASARI along with clinical, computational radiomic, and multi-omic features to construct combined neuro-oncological prediction models. Lastly, we discuss the challenges and limitations of currently performed models as well as the methods to overcome them using automatic feature extraction solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.